HHS In role
Jared Seehafer
Deputy Commissioner for Technology and Artificial Intelligence, FDA (first to hold the post)
The FDA's first Deputy Commissioner for Technology and Artificial Intelligence, selected September 8, 2026, for a newly created post. A life-science software founder who joined the FDA as an adviser in 2025, Seehafer is now the agency's senior leader for technology, software, and AI — the official who sets FDA-wide AI strategy while the agency races to automate its review work.
Role status — October 2026: Seehafer is the FDA’s first Deputy Commissioner for Technology and Artificial Intelligence, selected September 8, 2026, in a newly created position. HHS describes him as the agency’s senior leader for technology, software, and AI, charged with establishing FDA-wide strategy and priorities in those areas — a portfolio that did not exist as a deputy-commissioner job under any previous commissioner.
Seehafer arrives from the regulated world’s other side: per STAT’s account of his background, he joined the FDA as an adviser in 2025 after founding a life science software company and working in investment advising in biotech, and HHS credits him with two decades of technical and leadership experience spanning software, AI, and FDA-regulated medical technology. He is a technologist installed at the top of a science agency, not a career reviewer promoted into a tech title.
The job exists because the agency is already moving. The FDA launched Elsa, its generative AI tool, in June 2025, and staff now use it to review clinical protocols, evaluate scientific information, and identify high-priority inspection targets, under an administration-wide push to use AI to speed up regulatory review. Seehafer’s mandate, per HHS, is to turn that improvisation into strategy: accelerating what the department calls reliable AI innovation, modernizing federal technology, and building a regulatory framework for emerging technologies — while the same agency he helps lead decides how AI-driven medical products themselves get reviewed.
Why tracked here: Seehafer owns the question underneath half of the FDA’s 2026 fights — how fast the agency automates its own judgment, and who sets the rules for the AI tools arriving in medicine.
Sources (Oct 2026): HHS leadership announcement, Sept. 8, 2026; STAT, Sept. 8, 2026; RAPS, Sept. 8, 2026; R&D World, Oct. 2026.